Technical Analysis for KMPH - KemPharm, Inc.

Grade Last Price % Change Price Change
grade F 0.456 1.33% 0.01
KMPH closed down 8.16 percent on Tuesday, November 19, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical KMPH trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 1.33%
Stochastic Reached Oversold Weakness 1.33%
Wide Bands Range Expansion 1.33%
Oversold Stochastic Weakness 1.33%
Fell Below 20 DMA Bearish -6.94%
Volume Surge Other -6.94%
Calm After Storm Range Contraction -6.94%
Earnings Movers Other -6.94%
50 DMA Resistance Bearish -13.96%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -13.96%

Older signals for KMPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
KMPH Chart by TradingView
Basic chart:
Profile
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Health Pharmaceutical Pharmaceutical Industry Pain Medication FDA Pharmacokinetics Platform Technology Attention Deficit Hyperactivity Disorder Adhd Amphetamine Methylphenidate
Is KMPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 15 The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
Nov 15 KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2019 Results - Earnings Call Transcript
Nov 14 KemPharm EPS beats by $0.34, beats on revenue
Nov 14 KemPharm Reports Third Quarter 2019 Results
Nov 12 KemPharm to Report Third Quarter 2019 Results
Oct 31 KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019
Oct 22 KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
Oct 16 KemPharm files for $80M mixed shelf
Oct 3 ArQule (ARQL) in Focus: Stock Moves 6.2% Higher
Oct 3 KemPharm, Inc. (NASDAQ:KMPH): What Does Its Beta Value Mean For Your Portfolio?
See more KMPH news...
Indicators
Indicator Value
52 Week High 3.0
52 Week Low 0.45
Average Volume 174,111
200-Day Moving Average 1.3532
50-Day Moving Average 0.635
20-Day Moving Average 0.5105
10-Day Moving Average 0.5003
Average True Range 0.0771
ADX 24.62
+DI 23.5245
-DI 19.2094
Chandelier Exit (Long, 3 ATRs ) 0.4387
Chandelier Exit (Short, 3 ATRs ) 0.6813
Upper Bollinger Band 0.5895
Lower Bollinger Band 0.4315
Percent B (%b) 0.12
BandWidth 30.950049
MACD Line -0.0431
MACD Signal Line -0.0471
MACD Histogram 0.004
Fundamentals Value
Market Cap 6.6 Million
Num Shares 14.7 Million
EPS -3.10
Price-to-Earnings (P/E) Ratio -0.15
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.56
Resistance 3 (R3) 0.57 0.54 0.54
Resistance 2 (R2) 0.54 0.52 0.54 0.53
Resistance 1 (R1) 0.50 0.50 0.49 0.49 0.53
Pivot Point 0.47 0.47 0.47 0.47 0.47
Support 1 (S1) 0.43 0.45 0.42 0.42 0.37
Support 2 (S2) 0.40 0.43 0.40 0.37
Support 3 (S3) 0.36 0.40 0.36
Support 4 (S4) 0.35